Background: The safety and efficacy of new anticoagulants are often initially tested for venous thromboembolism (VTE) prevention in patients undergoing major orthopedic surgery. Concern among surgeons about the risks for bleeding may result in suboptimal use of thrombophylaxis. Objective: To evaluate the definitions used to define bleeding outcomes in studies of new anticoagulants and to examine the influence the definition has on the perceived bleeding risk of thromboprophylaxis. Methods: The MedLine database was searched for phase III studies of new anticoagulants versus the standard comparator, enoxaparin, in patients undergoing major orthopedic surgery. Results: The definitions for major bleeding outcomes varied widely both across and within clinical trial programs of new anticoagulants. Studies which did not include surgical site bleeding in their definition for major bleeding showed lower major bleeding rates in comparison to those that did include this outcome. Other factors that influenced the rate of major bleeding included the timing of prophylaxis initiation in relation to surgery and the dose of anticoagulant therapy. The wide range of definitions used for major bleeding made it difficult to compare bleeding risk among studies of new anticoagulants. Conclusions: The definitions of bleeding events that clinical trials of thromboprophylaxis use in their assessment of new anticoagulants strongly influences each drug's perceived safety profile and may underestimate bleeding risks. Clinical studies of new anticoagulants urgently need standardization of bleeding definitions to allow intertrial comparability and to ensure consistent reporting of clinically relevant outcomes.
Introduction
The safety and efficacy of new anticoagulants are often initially evaluated in major orthopedic surgery patients who are widely recognized as at high risk for venous thromboembolism (VTE). 1 Current guidelines for thromboprophylaxis in patients undergoing major orthopedic surgery advocate the use of anticoagulants such as low-molecular-weight heparins (LMWHs), fondaparinux, or vitamin K antagonists, 1 and numerous studies have shown that thromboprophylaxis has a good benefit-to-risk ratio in these patients. [2] [3] [4] [5] Bleeding raises major safety concerns for orthopedic surgeons that prescribe pharmacological thromboprophylaxis, 6 although the full clinical impact of VTE, and its status as the leading cause of preventable death in hospitals remains underrecognized. 7 In addition to VTE treatment and related mortality, the health care burden associated with long-term morbidities (such as pulmonary hypertension and postthrombotic syndrome) that may develop following VTE can be substantial. 8 This combination of limited awareness of the true burden of VTE and arguably disproportionate fear of bleeding may have led to the suboptimal use of thrombophylaxis in surgical patients despite the wealth of data supporting the risk-benefit of thrombophylaxis, as well as clear recommendations from international guidelines. 9 Bleeding concerns need to be balanced against the high risk of VTE associated with major orthopedic surgery. When selecting appropriate thromboprophylaxis, the surgeon must be able to balance the harms associated with a new anticoagulant versus their clinical benefits. Low-molecular-weight heparins have been intensively investigated in patients undergoing major orthopedic surgery, and multiple studies have demonstrated the efficacy and safety of thromboprophylaxis. As a result, current treatment guidelines for thromboprophylaxis after both elective hip and knee replacement surgeries give a grade IA recommendation for the use of LMWHs. 1 The incidence of major bleeding associated with LMWHs in patients undergoing major orthopedic surgery is low, reported rates ranging from 0.9% to 2.4%. 2, 3 Several new classes of anticoagulants, such as direct factor Xa inhibitors and thrombin inhibitors, have undergone development and rigorous evaluation for the indication of thromboprophylaxis. 10 Given that the anticoagulants currently recommended for thromboprophylaxis in patients undergoing major orthopedic surgery have proven efficacy for VTE prevention, improvements in the clinical benefit-to-risk ratio of these new anticoagulants may depend on increased safety.
In this review, we critically evaluate the definitions of bleeding end points used in phase III studies designed to assess the benefit-to-harm ratio of new anticoagulants in patients undergoing major orthopedic surgery. We also examine the influence of the definitions used on the perceived bleeding risk associated with an individual agent.
Challenges in Assessing Bleeding Risk of New Anticoagulants
Studies use more than 10 different terms to describe bleeding events (Table 1) .
For assessing bleeding risk associated with new anticoagulants, the broad range of bleeding event terminology creates difficulty.
Although the European Medicines Agency (EMEA) and International Society on Thrombosis and Haemostasis recently issued recommendations for the reporting of safety end points in thromboprophylaxis clinical trials, an internationally accepted guideline on the definitions for bleeding outcomes does not exist. 11, 12 The lack of standardized criteria to assess bleeding outcomes has resulted in the use of widely varying definitions across different studies of thromboprophylaxis treatments in orthopedic surgery patients (Table 1) . 13 As a result, it remains extremely challenging to assess and interpret the bleeding risks of the new anticoagulants.
Studies do not consistently report bleeding events of clinical relevance to orthopedic surgeons. Orthopedic surgeons typically have great concern about surgical-site bleeding, because much of the major bleeding observed in orthopedic patients occurs at the surgical site and major bleeding into a replaced joint can have a detrimental effect on clinical outcomes. 6 However, studies inconsistently report surgical-site bleeding across different drug development programs and throughout different phases of agent development. [14] [15] [16] [17] [18] [19] 378 Clinical and Applied Thrombosis/Hemostasis / Vol. 15, No. 4, August 2009 Bleeding Definitions Used During the Assessment of New Anticoagulants
The EMEA recommends that validated and clinically relevant classifications of bleeding should be used in studies investigating the safety and efficacy of new anticoagulants. 11 The EMEA definition for major bleeding is shown in Table 2 . [14] [15] [16] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The EMEA also recommends that the methods used for assessing bleeding should be consistent across an entire development program for a new anticoagulant and that bleeding events should be adjudicated by a central independent and blinded committee of experts. The definitions for major bleeding that were used in the phase III clinical studies of several new anticoagulants identified by the current literature search are compared with the EMEA recommendations in Table 2 . This comparison highlights the broad range of definitions used to describe major bleeding in these studies. Definitions for major bleeding consistently included fatal bleeding and critical bleeding. However, studies' definitions for major bleeding did not consistently include bleeding leading to treatment cessation and bleeding at the surgical site. The latter is of particular concern, given the previously discussed importance of this outcome to orthopedic surgeons. 6 Similar to the findings among studies for definitions of major bleeding, the phase II clinical studies did not consistently use definitions for nonmajor bleeding. The studies used vague definitions for minor bleeding, such as ''overt bleeding that did not meet the criteria for major bleeding,'' ''bleeding events not fulfilling the criteria of major or clinically significant bleeding,'' and ''clinically relevant nonmajor bleeding.'' Such unclear terminology makes interstudy comparisons difficult. 21, [25] [26] [27] 
Evaluation of Bleeding Outcomes Associated With New Anticoagulants
A literature search was conducted using the Med-Line database to identify phase III clinical studies of new anticoagulants for the prevention of VTE in patients undergoing major orthopedic surgery that have been published since 2000. The search terms used were ''knee surgery,'' ''hip surgery,'' ''orthopedic a These 2 studies referred to ''severe bleeding'' rather than ''major bleeding'' and the definition of ''severe bleeding'' included excessive bleeding from the operation wound, which was greater than that expected by the investigator. b These would be included in the definition of major bleeding as overt bleeding with bleeding index of 2; bleeding index defined as the number of units of packed red blood cells or whole blood transfused, plus the hemoglobin values before the bleeding episode, minus the hemoglobin values after the episode. c Only extrasurgical site bleeding. d Not included in the formal definition but consistently reported in the study publications. surgery,'' ''arthroplasty.'' Given that enoxaparin is widely regarded as the treatment of choice for the prevention of VTE in patients undergoing major orthopedic surgery, the search was restricted to studies which used enoxaparin as an active comparator, and search terms also included ''enoxaparin'' and ''low-molecular-weight heparin.'' The literature review excluded studies, which were not published in English, had only been published in abstract form, did not include definitions for major bleeding, or were prematurely terminated. The major bleeding definitions used and results for the phase III clinical studies of new anticoagulants in patients undergoing major orthopedic surgery that were identified by the literature search conducted for this review are summarized in Tables  2 and 3 . [14] [15] [16] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Enoxaparin Studies that evaluate the efficacy and safety of new anticoagulants typically use enoxaparin as the ''gold standard'' treatment for thromboprophylaxis after major orthopedic surgery. The studies which demonstrated the safety and efficacy of enoxaparin in patients undergoing major orthopedic surgery used unfractionated heparin as the comparator. Researchers conducted these studies in the late 1980s and early 1990s prior to the current recommendations for standard definitions of major bleeding in clinical investigations of new anticoagulants. [29] [30] [31] [32] [33] Therefore, these studies did not all include precise definitions of major bleeding. Where such a definition was provided, it included bleeding that was overt and associated with a fall in the hemoglobin level of 20 g/L or a need for transfusion of 2 units of blood and critical bleeding (eg, retroperitoneal or intracranial). [29] [30] [31] These studies demonstrated that enoxaparin had similar 30, 32, 33 or reduced major bleeding outcome rates 29, 31 when compared to unfractionated heparin.
Fondaparinux
Fondaparinux is a synthetic pentasaccharide which indirectly inhibits factor Xa. Four phase III studies of patients undergoing major orthopedic surgery evaluated the safety and efficacy of fondaparinux: 2 studies in elective hip replacement surgery 14, 20 ; 1 study in hip fracture surgery 21 ; and 1 study in elective major knee surgery 22 (Table 3 ). All 4 studies used the same definition for major bleeding ( Table 2 ).
In 2 studies of fondaparinux in patients undergoing elective hip replacement surgery and in the study of patients undergoing hip fracture surgery, there was no significant difference in major bleeding between patients randomized to fondaparinux and those randomized to enoxaparin (Table 3) . 14, 20, 21 In these 3 studies, the majority of reported major bleeding events occurred at the surgical site in all treatment groups. In the studies of patients undergoing hip replacement surgery, the 2 groups of patients had similar rates of ''other'' (nonmajor) bleeding events and transfusion requirements. 14, 20 In the study of patients undergoing hip fracture surgery, patients receiving fondaparinux had a higher rate of minor bleeding events than those who received enoxaparin (4.1% and 2.1%, respectively; P ¼ .02); the groups did not have statistically significant different rates of transfusion requirements. 21 In a study of patients undergoing elective major knee surgery, fondaparinux had a higher incidence of major bleeding compared with enoxaparin ( Table 3) . 22 In contrast, the 2 treatment groups had a similar incidence of other bleeding and postoperative transfusions.
A meta-analysis of the 4 studies assessing fondaparinux versus enoxaparin for the prevention of VTE in major orthopedic surgery also showed that fondaparinux had a significantly higher incidence of major bleeding compared to enoxaparin (2.7% versus 1.7%, respectively; P ¼ .008). 5 Excess bleeding, defined by a bleeding index of 2, mainly accounted for the difference in major bleeding between the randomized groups.
The meta-analysis also indicated that the timing of thromboprophylaxis initiation influenced the comparative safety profile of fondaparinux and enoxaparin. 5 Both the incidence of major bleeding and the incidence of overt bleeding with a bleeding index of 2 were significantly related to the timing of the first fondaparinux injection (P ¼ .008 for both associations). The occurrence of a bleeding index of 2 decreased when the first fondaparinux injection was given 6 hours or more after the completion of surgery, and the rates became similar for the randomized treatment groups.
Ximelagatran
The oral direct thrombin inhibitor, ximelagatran, was withdrawn from the market because of hepatotoxicity concerns. 34 Prior to this, the safety and These bleeding events were termed ''severe'' rather than ''major''; no formal statistical comparisons of bleeding parameters were performed in these studies.
Assessing the Safety of Novel Anticoagulants / Hull et al 383 efficacy of ximelagatran were compared with enoxaparin in 3 studies of patients undergoing major orthopedic surgery: 2 studies were in patients undergoing either total hip or knee replacement surgery, 16, 23 and the other study only included patients who were undergoing total hip replacement surgery. 15 The former 2 studies defined bleeding outcomes differently than the latter study ( Table 2 ). Similar to the fondaparinux studies, the 2 studies of melagatran/ximelagatran in patients undergoing total hip-or knee-replacement surgery indicated that the timing of the initial melagatran dose may influence its safety profile (Table 3) . 16, 23 When the initial dose of melagatran was given immediately before surgery, severe bleeding occurred in a greater proportion of patients receiving melagatran/ximelagatran who underwent total hip replacement surgery or total knee replacement surgery, compared with enoxaparin. Most of the severe bleeding was excessive bleeding from the operation wound, which the investigator judged to be greater than that normally expected. 16 In contrast, when the initial dose of melagatran was given 4 to 12 hours after surgery, a similar proportion of melagatran/ximelagatran and enoxaparin treated patients who underwent either total hip or knee replacement surgery experienced severe bleeding. 23 There were no differences in major or minor bleeding events in the study which compared the postoperative use of ximelagatran and enoxaparin in patients undergoing total hip replacement surgery. 15 The majority of the major bleeding events were wound hematomas and occurred within 3 days of surgery.
Dabigatran
Two phase III studies of patients undergoing total knee replacement and 1 study of patients undergoing total hip replacement surgery have evaluated the safety and efficacy of dabigatran, an oral direct thrombin inhibitor. 18, 25, 26 The studies all used EMEA guidelines to define major bleeding, clinically relevant nonmajor bleeding, and minor bleeding events. 11 These standard definitions allow comparisons of bleeding rates to other studies that use the same definitions.
The phase III studies of patients undergoing total knee or hip replacement surgery did not show statistically significantly different major bleeding rates between either dose of dabigatran and enoxaparin (Table 3) . 18, 25, 26 Most of the major bleeding events in the 2 treatment arms of both studies occurred at the surgical site. Numerically more patients undergoing hip-versus knee-replacement surgery experienced major bleeding. Most of the major bleeding events in the hip replacement study were clinically overt and associated with 20 g/L or more fall in hemoglobin, or clinically overt and leading to transfusion of 2 units of packed cells or whole blood. In both studies, the dabigatran and enoxaparin groups had similar rates of clinically relevant nonmajor bleeding.
Rivaroxaban
Two published phase III studies of patients undergoing total hip replacement surgery, 27,28 and 1 published phase III study of patients undergoing total knee replacement surgery 19 have evaluated rivaroxaban, an oral direct factor Xa inhibitor. Another phase III study of rivaroxaban in patients undergoing total knee replacement surgery, published only in abstract form, was ineligible for inclusion in the current review.
The published rivaroxaban thromboprophylaxis phase III studies in major orthopedic surgery have indicated that patients randomized to treatment with either rivaroxaban or enoxaparin have a similar incidence of major bleeding and any bleeding (Table 3) . 19, 27, 28 In addition, rivaroxaban and enoxaparin have shown similar incidences of the following bleeding outcomes in all 3 studies: the combined end point of major and clinically relevant nonmajor bleeding events; hemorrhagic wound complications; and the proportion of patients receiving blood transfusions. In 1 of the studies, there were no reports of major surgical site bleeding in either of the treatment groups. 28 The phase III studies that evaluated rivaroxaban versus enoxaparin in patients undergoing major orthopedic surgery did not include bleeding at the site of surgery or bleeding that prompted termination of the study medication as part of their definition of major bleeding. 19, 27, 28 As a consequence of the exclusion of these events from the definition of major bleeding, the rivaroxaban studies showed significantly lower rates of major bleeding than those seen in similar studies of other anticoagulants. 5, 18, 23, 26 The definition of major bleeding used in the rivaroxaban phase III studies therefore creates difficulty in the accurate interpretation of these data in comparison with other new anticoagulants.
Contrary to EMEA guidance, 11 the rivaroxaban phase II and phase III studies used different definitions of major bleeding . 17, 35, 36 The definition of major bleeding used in the phase II studies included bleeding leading to treatment discontinuation and surgical site bleeding, whereas the definition used in the phase III studies did not include these terms.
Consequently, it is difficult to compare the results for major bleeding within the rivaroxaban clinical trial program. For example, the higher major bleeding rates that were seen in the phase II studies of rivaroxaban 10 mg (0.7%-2.3%) compared with those in the phase III studies (<0.1%-0.6%) may have at least partially resulted from the exclusion of surgical site bleeding from the definition of major bleeding in the phase III studies. Furthermore, although the majority of the major bleeding events in the phase II rivaroxaban studies were recorded as surgical site bleedings, the reporting of these events as part of a composite wound hematoma outcome makes it difficult to obtain equivalent surgical site data from phase III trial peer-reviewed publications.
Assessment of Clinical Benefit-To-Harm Ratio
Most of the phase III clinical studies included in this literature review demonstrated that new thromboprophylaxis agents had efficacy at least as effective as enoxaparin in patients undergoing major orthopedic surgery. 14, 16, [18] [19] [20] [21] [22] 25, 27, 28 However, an assessment of the overall benefit-to-harm ratio of the new thromboprophylactic agents requires an accurate assessment of the bleeding risk.
Phase III studies of fondaparinux, ximelagatran, and dabigatran, and phase II studies of rivaroxaban demonstrated that most of the major bleeding events occurred at the surgical site. The studies reviewed highlight how definitions used for bleeding outcomes can influence the bleeding rates associated with new anticoagulants. For example, the exclusion of surgical site bleeding from the definition for major bleeding in the phase III studies of rivaroxaban produced the low rates of major bleeding. 19, 27, 28 The studies in this review also demonstrate that the timing of prophylaxis initiation in relation to major orthopedic surgery affects the risk of anticoagulantrelated bleeding. For example, fondaparinux initiated <6 hours postoperatively was associated with increased major bleeding compared with the initiation of this anticoagulant 6 hours after surgery. 5 In addition, preoperative but not postoperative initiation of ximelagatran was shown to be associated with an increased risk of serious bleeding compared with the LMWHs. 37 In general, data from clinical trials indicated that VTE prevention in patients undergoing major orthopedic surgery does not require preoperative anticoagulant administration and initiation of anticoagulant therapy within 2 hours of surgery increases the risk for major bleeding. In contrast, initiation within 6 to 9 hours of surgery is effective without any increased risk for major bleeding. 38 When anticoagulant therapy is administered close to the time of surgery, the initial dose should be carefully refined for individual patients to maximize efficacy without increasing bleeding risk. For example, initial dosing was halved in the studies evaluating the safety and efficacy of dabigatran in patients with normal hemostasis. 18, 25, 26 Procedure-related major surgical site bleeding must be differentiated from anticoagulant therapyrelated events when assessing the benefit-to-harm ratio associated with anticoagulants. To address this issue, 2 of the ximelagatran studies used a subjective, nonvalidated assessment of surgical site bleeding related to anticoagulant therapy which required investigators to report excessive (greater than expected) bleeding from the operation wound. 16, 23 Other studies reported major bleeding outcomes before and after the first dose of anticoagulant therapy. For example, in the study of dabigatran and enoxaparin in patients undergoing hip replacement surgery, approximately half of all major bleeding events in the dabigatran group were surgeryrelated, occurring before anticoagulant initiation. 25 Similarly, in the North American Fragmin Trial (NAFT), which compared pre-and postoperative dalteparin with postoperative warfarin in patients undergoing hip replacement surgery, the major bleeding rate in the warfarin group on the first postoperative day was 4.1%. As warfarin therapy was only initiated in the evening after surgery, this reflects the usual bleeding rate associated with surgery. 39 The relevance of certain major bleeding outcomes and definitions to clinical practice is questionable. For example, the relevance of the bleeding index used in fondaparinux and ximelagatran studies, defined as the number of units of packed red blood cells or whole blood transfused plus the prebleeding minus post-bleeding hemoglobin levels in g/dL, remains unclear. While patients treated with fondaparinux had a higher frequency Assessing the Safety of Novel Anticoagulants / Hull et al 385 of bleeding events associated with a bleeding index of 2, versus enoxaparin-treated patients, the 2 groups had similar rates for the following established clinically important outcomes: fatal bleeding; critical organ bleeding; bleeding leading to reoperation; wound infection; surgical site complications leading to prolonged hospitalization. 5 Additionally, given the importance of surgical site bleeding to orthopedic surgeons, and that these account for the majority of major bleeding events in other studies of anticoagulants, major bleeding definitions that exclude these events, such as those used in the rivaroxaban phase III studies become insufficiently informative. 14, 16, 18, 20, 25, 26 The benefit-to-risk profile of new anticoagulants established in clinical trials may differ from that subsequently observed in real-life clinical practice. In France, postmarketing surveillance that detected a greater than expected number of cases of serious bleeding related to fondaparinux led to a safety analysis of adverse drug reactions in December 2006. 40 An analysis of the national pharmacovigilance database showed that 122 hemorrhagic accidents occurred between January 2005 and January 2007, including serious events where patients required blood transfusions, new surgical therapy, or hospitalization for observation. Off-label use of fondaparinux, for example in patients with contraindications such as cardiac arrhythmia, occurred in 38% of these cases.
Adjudication of Bleeding Outcomes
The method used to adjudicate and classify bleeding outcomes can also influence the bleeding results and consequently the perceived risk profile of new anticoagulants. The EMEA recommends that central independent and blinded committees of experts adjudicate bleeding events. Most clinical studies evaluating new anticoagulants in patients undergoing major orthopedic surgery now follow the EMEA recommendations. The adjudication of bleeding events by central committees ensures that investigators consistently apply definitions for bleeding events across a clinical study. However, adjudication committees only have access to information in case report forms on the criteria used to define bleeding events. Alternatively, individual study investigators could determine the importance of bleeding events based on their own judgment. These 2 methods for classifying bleeding outcomes can give rise to different results. For example, in NAFT, major bleeding was reported by study investigators and also by a central adjudication committee. 39 Preoperative dalteparin was associated with a significant increase in major bleeding compared with warfarin when reported by the central adjudication committee (8.9% versus 4.5%, respectively; P ¼ .01). In contrast, study investigators reported fewer major bleeding events and no significant difference between the treatment groups. 39 This study highlights that central adjudication committees lack clinical perspective at the bedside and may overestimate major bleeding from case report forms due to the difficulty in discriminating between usual operative bleeding, and increased bleeding for the perioperative and immediate postoperative period. These results also suggest that studies should report bleeding rates from both central committees and study investigators. 41 
Conclusions
The safety and efficacy of several new anticoagulants have recently been evaluated in large studies of patients undergoing major orthopedic surgery. The broad range of definitions used to classify bleeding outcomes in these studies makes it difficult to interpret the comparative bleeding risk associated with these new anticoagulants. Furthermore, the relevance of the reporting of major bleeding in these trials to real-life surgical practice is questionable, particularly those from studies which did not include surgical site bleeding.
Our review highlights how the definitions of bleeding events used in clinical studies of new anticoagulants can strongly influence the perceived safety profile of new anticoagulants and can potentially lead to an underestimation of the bleeding risk associated with thromboprophylaxis. With many new anticoagulants currently in clinical development, there is an urgent need for standardization of bleeding definitions for studies of new anticoagulants to allow intertrial comparability and to ensure the consistent reporting of clinically relevant outcomes.
